The FDA has finally approved the first generic of GlaxoSmithKline’s Advair blockbuster respiratory diseases inhaler, after years of delays. Even though Advair’s main patent expired in 2010 and ...

But this is likely only a stay of execution for Advair. It’s common for the FDA to reject generics, and with Mylan’s product there is the added complication of producing an inhaler device ...

Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is ... daily from a Diskus™ inhaler for a 4-week run ...